I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filling system in

accordance with § 1.6(a)(4).

Dated: <u>January 25, 2010</u> Signature: <u>/Debra J. Milasincic, Esq./</u> (Debra J. Milasincic, Esg.)

Docket No.: KZY-004US

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Christian Widmann *et al*.

Application No.: 10/563,536 Confirmation No.: 8023

Filed: June 16, 2006 Art Unit: 1656

For: RASGAP DERIVED PEPTIDE FOR

SELECTIVELY KILLING CANCER CELLS

Examiner: C. M. Kam

AMENDMENT IN RESPONSE TO NON-FINAL OFFICE ACTION

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the Office Action dated July 23, 2009 (Paper No. 20090718), please amend the above-identified U.S. patent application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 9 of this paper.